Patterns of Patient-Reported Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer Survivors
Search for other papers by Christina Teng in
Current site
Google Scholar
PubMed
Search for other papers by Venkatesha in
Current site
Google Scholar
PubMed
Search for other papers by Prunella L. Blinman in
Current site
Google Scholar
PubMed
Search for other papers by Janette L. Vardy in
Current site
Google Scholar
PubMed
Background: Chemotherapy-induced peripheral neuropathy (CIPN) can be a debilitating toxicity of oxaliplatin used for treatment of colorectal cancer (CRC). We aimed to assess CIPN symptoms and associations in our colorectal survivorship population and review the impact of neurotoxicity on dose delivery of oxaliplatin. Patients and Methods: Patients attending their first visit to the Sydney Cancer Survivorship Centre following completion of adjuvant treatment for CRC completed comprehensive patient-reported outcome measures, including symptoms, quality of life (QoL), alcohol intake, and exercise habits. Participants scored symptoms of “numbness or pins and needles” in hands or feet from 0 (no trouble at all) to 10 (worst I can imagine). Diagnosis, treatment, and comorbidity details were obtained from medical records. A subset of patients completed serial assessments of PN symptoms at follow-up visits. Results: Data were analyzed from 233 patients (52% male; mean age, 63 years) with CRC attending their first visit at the Sydney Cancer Survivorship Centre. A subset of 104 patients were included in the longitudinal analysis. The odds of patient-reported numbness were significantly higher in patients receiving oxaliplatin (odds ratio, 5.6; 95% CI, 3.2–9.8), with 72.4% of oxaliplatin-treated CRC survivors reporting numbness an average of 5.9 months after chemotherapy. Mean patient-reported numbness was significantly higher in those who received oxaliplatin-containing chemotherapy (mean, 3.31) compared with fluoropyrimidines alone (mean, 1.37) and no chemotherapy (mean, 0.66). Of the patients receiving oxaliplatin, 80% required dose reduction or early cessation, with PN the most common reason reported. QoL in physical, emotional, and functional well-being domains was lower in patients with numbness. We found a weak negative association between numbness score and age, and between (1) numbness and cardiovascular disease and (2) numbers and pain score. Conclusions: CIPN symptoms are common in CRC survivors who have received oxaliplatin and are associated with lower QoL. Neurotoxicity is underreported in clinical trials compared with real-world populations and is a major barrier to oxaliplatin treatment delivery.
Submitted February 27, 2022; final revision received June 19, 2022; accepted for publication June 30, 2022.
Author contributions: Conceptualization: Teng, Blinman, Vardy. Data curation: Teng, Venkatesha, Vardy. Formal analysis: Teng, Venkatesha. Investigation: Teng, Vardy. Methodology: Teng, Venkatesha, Blinman, Vardy. Project administration: Teng, Venkatesha. Visualization: Teng, Blinman. Writing—original draft: Teng, Venkatesha, Vardy. Writing—review and editing: Teng, Venkatesha, Blinman, Vardy. Validation: Venkatesha. Supervision: Blinman, Vardy.
Disclosures: The authors have disclosed that they have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article.
© 2019-2024 National Comprehensive Cancer Network